Citigroup Inc Longboard Pharmaceuticals, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Longboard Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 30,466 shares of LBPH stock, worth $1.83 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

30,466

Previous 10,471 190.96%

Holding current value

$1.83 Million

Previous $283,000 258.66%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$27.58 - $39.5 $551,462 - $789,802	19,995 Added 190.96%	30,466 $1.02 Million
Q2 2024 Aug 12, 2024	BUY	$17.0 - $27.03 $6,579 - $10,460	387 Added 3.84%	10,471 $283,000
Q1 2024 May 10, 2024	BUY	$18.89 - $26.06 $147,946 - $204,101	7,832 Added 347.78%	10,084 $217,000
Q4 2023 Feb 09, 2024	BUY	$3.68 - $6.5 $8,261 - $14,592	2,245 Added 32071.43%	2,252 $13,000
Q3 2023 Nov 09, 2023	SELL	$5.49 - $7.49 $25,424 - $34,686	-4,631 Reduced 99.85%	7 $0
Q2 2023 Aug 10, 2023	BUY	$4.19 - $10.05 $7,835 - $18,793	1,870 Added 67.56%	4,638 $34,000
Q1 2023 May 11, 2023	BUY	$3.84 - $5.96 $10,629 - $16,497	2,768 New	2,768 $11,000
Q3 2022 Nov 10, 2022	SELL	$2.95 - $4.7 $626,565 - $998,256	-212,395 Reduced 65.35%	112,605 $419,000
Q2 2022 Aug 10, 2022	BUY	$2.96 - $5.38 $503,812 - $915,713	170,207 Added 109.96%	325,000 $1 Million
Q1 2022 May 12, 2022	SELL	$4.0 - $6.0 $180,828 - $271,242	-45,207 Reduced 22.6%	154,793 $803,000
Q4 2021 Feb 10, 2022	BUY	$4.75 - $9.45 $950,000 - $1.89 Million	200,000 New	200,000 $968,000

Others Institutions Holding LBPH

# of Institutions

126

Shares Held

34.9M

Call Options Held

28.9K

Put Options Held

13.9K

View Full List

About Longboard Pharmaceuticals, Inc.

Ticker LBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,586,000
Market Cap $815M
Description
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical ...

More about LBPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account